注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Denali Therapeutics Inc是一家生物製藥公司。該公司專注於發現和開發針對神經退行性疾病患者的療法,包括阿爾茨海默病、帕金森病、肌萎縮側索硬化症(ALS)等。該公司的臨床項目包括富含亮氨酸的重複激酶2(LRRK2)抑製劑項目、真核起始因子2 B(EIF2B)激活劑項目、酶轉運載體:艾杜糖酸2-硫酸酯酶(ETV:IDS)項目、受體相互作用的絲氨酸/蘇氨酸蛋白激酶1(RIPK1)抑製劑項目和次級非中樞神經系統(CNS)滲透RIPK1抑製劑。該公司設計其候選產品以穿過血腦屏障(BBB),並直接作用於大腦。其項目管線包括大約15個基於其電視技術的項目,包括領先的項目ETV:IDS(DNL310)。其產品線包括DNL151、DNL593(PTV:PGRN)、DNL126(ETV:SGSH)、DNL788、DNL343和DNL758。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Jay T. Flatley | 71 | 2015 | Independent Director |
David P. Schenkein | 67 | 2015 | Independent Director |
David M. Holtzman | - | 2020 | Member of Scientific Advisory Board |
Peter S. Klein | 62 | 2018 | Independent Director |
Kevan M. Shokat | - | 2023 | Member of Scientific Advisory Board |
Stacie Weninger | - | 2021 | Member of Scientific Advisory Board |
Henrik Zetterberg | - | 2019 | Member of Scientific Advisory Board |
Eric M. Reiman | - | - | Member of Scientific Advisory Board |
Melissa A. Starovasnik | 58 | 2021 | Member of Scientific Advisory Board |
Nancy A. Thornberry | 67 | 2021 | Independent Director |
Marc Tessier-Lavigne | 64 | 2015 | Co-Founder & Independent Director |
Vicki L. Sato | 75 | 2015 | Independent Chairperson |
Ryan J. Watts | 48 | 2015 | Co-Founder, President, CEO & Director |
Steve Edward Krognes | 56 | 2015 | Director |
Scott A. Biller | 68 | - | Member of Scientific Advisory Board |
Jennifer E. Cook | 58 | 2018 | Independent Director |
Erik Harris | 53 | 2022 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核